Lead Opportunity Target biopharma buyers focused on disease-modifying Alzheimer’s therapies by outreach highlighting Acumen’s lead candidate sabirnetug (ACU193) and its Phase 2 ALTITUDE-AD program, emphasizing potential partnership or licensing opportunities in late-stage development.

Strategic Partnerships Engage potential collaborators around AdTech and data analytics with Acumen’s recent collaboration interests, such as Unlearn and JCR, to offer joint data analysis, real-world evidence studies, or AI-driven program analysis to accelerate trials.

Clinical Differentiation Position Acumen’s Enhanced Brain Delivery technology and high-selectivity anti-AβO antibodies as unique value propositions to investors and potential co-development partners seeking novel mechanisms to target toxic Aβ oligomers in Alzheimer’s.

Investor Readiness Leverage visible investor activity from conferences and press coverage to time outreach around funding milestones, with a focus on securing strategic investors or grants that support Phase 2 progression and manufacturing scale for sabirnetug.

Operations Fit Align sales outreach with Acumen’s mid-sized profile and tech stack maturity to propose centralized contract manufacturing, clinical supply management, and digital workflow optimization using their existing systems (Sage Intacct, SAP, Microsoft 365, Power Automate) to improve trial operations.